{"filing":{"accession_number":"0001628280-26-053304","cik":"0001411685","ticker":"VTGN","company_name":"Vistagen Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-05","report_date":"2026-08-04","primary_document":"vtgn-20260804.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1411685/000162828026053304/vtgn-20260804.htm"},"events":[{"id":24953,"run_id":22623,"accession_number":"0001628280-26-053304","anchor_item_number":"3.01","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"summary":"Vistagen received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2). The company has not yet cured the deficiency and faces potential delisting if it fails to comply by February 1, 2027. This is a classic delisting-risk disclosure under Item 3.01, materially affecting the company's continued listing status and investor confidence.","company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","filing_date":"2026-08-05","form":"8-K","submitted_at":null,"items":[{"id":25663,"accession_number":"0001628280-26-053304","item_number":"3.01","item_title":"Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"Vistagen received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2). The company has not yet cured the deficiency and faces potential delisting if it fails to comply by February 1, 2027. This is a classic delisting-risk disclosure under Item 3.01, materially affecting the company's continued listing status and investor confidence.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T02:38:15.574504+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":25663,"accession_number":"0001628280-26-053304","item_number":"3.01","item_title":"Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"Vistagen received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2). The company has not yet cured the deficiency and faces potential delisting if it fails to comply by February 1, 2027. This is a classic delisting-risk disclosure under Item 3.01, materially affecting the company's continued listing status and investor confidence.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T02:38:15.574504+00:00","company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","filing_date":"2026-08-05"}]}